Related references
Note: Only part of the references are listed.Baseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2014)
Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12 440 patients of the ESC Heart Failure Long-Term Registry
Aldo P. Maggioni et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)
John J. V. McMurray et al.
EUROPEAN JOURNAL OF HEART FAILURE (2013)
The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial
Scott D. Solomon et al.
LANCET (2012)
Concomitant Angiotensin AT1 Receptor Antagonism and Neprilysin Inhibition Produces Omapatrilat-like Antihypertensive Effects Without Promoting Tracheal Plasma Extravasation in the Rat
Laxminarayan G. Hegde et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Improving Evidence-Based Care for Heart Failure in Outpatient Cardiology Practices Primary Results of the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF)
Gregg C. Fonarow et al.
CIRCULATION (2010)
Pharmacokinetics and Pharmacodynamics of LCZ696, a Novel Dual-Acting Angiotensin Receptor-Neprilysin Inhibitor (ARNi)
Jessie Gu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
Luis Miguel Ruilope et al.
LANCET (2010)
Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema
R. M. Fryer et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Interactions between angiotensin II and atrial natriuretic peptide in renomedullary interstitial cells: The role of neutral endopeptidase
Christine Maric et al.
NEPHRON PHYSIOLOGY (2006)
Molecular physiology of natriuretic peptide signalling
M Kuhn
BASIC RESEARCH IN CARDIOLOGY (2004)
Omapatrilat and enalapril in patients with hypertension: The omapatrilat cardiovascular treatment vs. enalapril (OCTAVE) trial
OB Kostis et al.
AMERICAN JOURNAL OF HYPERTENSION (2004)
Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition
NLM Cruden et al.
HYPERTENSION (2004)
Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction - Results of the CHARM low-left ventricular ejection fraction trials
JB Young et al.
CIRCULATION (2004)
Comparison of omapatrilat chronic and enalapril in patients with heart failure - The omapatrilat versus enalapril randomized trial of utility in reducing events (OVERTURE)
M Packer et al.
CIRCULATION (2002)
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
JN Cohn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Adrenomedullin (ADM) in the human forearm vascular bed:: effect of neutral endopeptidase inhibition and comparison with proadrenomedullin NH2-terminal 20 peptide (PAMP)
IB Wilkinson et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2001)
Effect of carvedilol on survival in severe chronic heart failure.
M Packer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: A new health status measure for heart failure
CP Green et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2000)
Share Paper
